A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR201 in the Treatment of Subjects With Parkinson's Disease

General Information

Summary

The goal of this clinical trial is to evaluate the safety, tolerability and preliminary efficacy that NCR201 has on Parkinson's disease (PD) patients.

Description

Parkinson's disease (PD) is a common neurodegenerative disease in the middle-aged and elderly. It is the "third killer" of the middle-aged and elderly after tumors and cardiovascular and cerebrovascular diseases. Its main clinical manifestations are resting tremor, reduced voluntary movement, muscle rigidity, postural reflex impairment, and autonomic dysfunction, which seriously affect patients' work ability and quality of life. It is estimated that nearly 100,000 people in China become new Parkinson's patients every year. Experts from the World Health Organization predict that the number of Parkinson's patients in China will reach 5 million in 2030, which will be more than half of the world's total. As the disease progresses, the symptoms of Parkinson's patients will become increasingly severe. The high prevalence and high disability rate of Parkinson's disease bring heavy burdens to individuals, families, and society.

Clinical trials phase

Phase 1

Start date (estimated)

2025-06-06

End date (estimated)

2028-12-01

Clinical feature

Label	Parkinson's disease
Link	http://purl.obolibrary.org/obo/DOID_14330
Description	A synucleinopathy that has_material_basis_in degeneration of the central nervous system that often impairs motor skills, speech, and other functions.; Xref MGI. OMIM mapping confirmed by DO. [SN].

Administrative Information

NCT number

NCT06978920

ICTRP weblink

https://trialsearch.who.int/Trial2.aspx?TrialID=NCT06978920

Other study identifiers

Name	NCR201-2001

Source weblink

https://clinicaltrials.gov/study/NCT06978920

Cells

Which differentiated cell type is used

Label	dopaminergic neuron
Link	http://purl.obolibrary.org/obo/CL_0000700
Description	A neuron that releases dopamine as a neurotransmitter.

Recruitment

Recruitment Status

Recruiting

Estimated number of participants